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During acute stress in the endoplasmic reticulum
(ER), mammalian prion protein (PrP) is temporarily
prevented from translocation into the ER and instead
routed directly for cytosolic degradation. This ‘‘pre-
emptive’’ quality control (pQC) system benefits cells
by minimizing PrP aggregation in the secretory path-
way during ER stress. However, the potential toxicity
of cytosolic PrP raised the possibility that persistent
pQC of PrP contributes to neurodegeneration in
prion diseases. Here, we find evidence of ER stress
and decreased translocation of nascent PrP during
prion infection. Transgenic mice expressing a PrP
variant with reduced translocation at levels expected
during ER stress was sufficient to cause several mild
age-dependent clinical and histological manifesta-
tions of PrP-mediated neurodegeneration. Thus, an
ordinarily adaptive quality-control pathway can be
contextually detrimental over long time periods. We
propose that one mechanism of prion-mediated
neurodegeneration involves an indirect ER stress-
dependent effect on nascent PrP biosynthesis and
metabolism.
INTRODUCTION
Several neurodegenerative diseases are caused by aberrant me-
tabolism of the widely expressed cell surface glycoprotein PrP
(reviewed in Prusiner, 1998; Collinge and Clarke, 2007; Aguzzi
et al., 2008). These diseases can be inherited through PrP muta-
tions or acquired via a transmissible agent composed largely of
a misfolded isoform of PrP termed PrPSc. Exogenous PrPSc is
capable of converting the normal cellular isoform (PrPC) into
additional PrPSc molecules, leading to its accumulation and gen-
erating additional transmissible agent. In the familial diseases,
PrP mutations appear to cause accumulation of misfolded PrP
through poorly understood mechanisms that in some cases
also generate PrPSc. Thus, altered PrP folding, metabolism,
and accumulation are the proximal causes of both familial and
transmissible prion diseases. However, the downstream events
that culminate in selective neuronal death in any of these
diseases are unknown.DevelopmeAlthough it was originally assumed that the accumulation of
misfolded PrP aggregates (e.g., PrPSc) would be intrinsically
damaging to neurons, this view proved overly simplistic. Early
tissue grafting experiments demonstrated that brain regions
knocked out for the Prnp gene were immune to degeneration
caused by PrPSc deposition (Brandner et al., 1996). More re-
cently, selective postnatal knockout of Prnp in neurons halted
and even reversed the damage caused by either pre-existing
PrPSc or newly generated PrPSc made by adjacent nonneuronal
cells (Mallucci et al., 2003, 2007). These observations have led to
the conclusion that ongoing PrP expression is obligate for neuro-
nal damage caused by PrPSc, suggesting that neurotoxic mole-
cule(s) are actively generated from newly synthesized cellular
PrP.
Two nonmutually exclusive models can explain this require-
ment for PrP expression. The most widely considered possibility
is that conversion of PrPC to PrPSc, or perhaps the clearance of
newly synthesized PrPSc, generates an intermediate species or
byproduct that is neurotoxic (e.g., as proposed by Collinge and
Clarke, 2007). Thus, toxicity is a cell-autonomous consequence
of ongoing PrPSc replication and clearance, a process absolutely
dependent on PrPC expression. At present however, PrPSc pro-
duction or clearance in a cellular context is poorly understood
and direct evidence for a hypothetical neurotoxic intermediate
or byproduct is lacking. A less obvious model is one in which
PrPSc accumulation alters cellular metabolism in a manner that
causes nascent PrPC to be made in a neurotoxic form (e.g., as
proposed in Hegde et al., 1999). One example of such altered
metabolism may be ER stress, a commonly observed feature
of various neurodegenerative diseases (Lindholm et al., 2006) in-
cluding those caused by PrP (reviewed in Hetz and Soto, 2006).
Furthermore, simply applying PrPSc to cultured cells causes dys-
regulation of ER Ca2+ homeostasis and leads to ER stress (Hetz
et al., 2003). While these observations highlight at least one ad-
verse consequence of PrPSc on cellular function, it has been un-
clear how such a general effect could cause neurodegeneration
that is both cell-type-specific and dependent on active PrP
expression.
A plausible way to link PrPSc-mediated ER stress to changes in
PrPCmetabolism recently emerged through the discovery of pre-
emptive quality control (pQC). The pQC pathway selectively
aborts the ER translocation of certain secretory and membrane
proteins during acute ER stress to allow their direct protea-
some-mediated degradation in the cytosol (Kang et al., 2006).
This pathway protects cells from excessive nascent protein entry
into and misfolding within the ER lumen during conditions ofntal Cell 15, 359–370, September 16, 2008 ª2008 Elsevier Inc. 359
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substrate, its translocation into the ER is partially attenuated
by ER stress caused by a variety of independent mechanisms
(Kang et al., 2006; Orsi et al., 2006). Thus, at least one potential
effect of PrPSc accumulation during prion disease progression is
to cause ER stress-induced routing of at least some nascent PrP
through the pQC pathway. Whether such chronic PrP degrada-
tion via pQC actually occurs during prion disease, and if this re-
routing might contribute to the pleiotropic neurodegenerative
phenotypes in prion diseases, is unclear.
Intriguingly, forced cytosolic expression of a PrP construct
lacking ER targeting and GPI-anchoring signals (DSS-PrP) can
cause severe neurodegeneration (Ma et al., 2002). However,
the significance of this observation to neurodegeneration ob-
served in prion diseases has been unclear (Fioriti et al., 2005;
Roucou et al., 2003). Not only is expression of DSS-PrP nonphy-
siological, but the phenotype and neuropathology are highly
atypical for either transmissible or genetic prion diseases in an-
imals or humans. Furthermore, evidence for cytosolic PrP gener-
ation by retrotranslocation from the ER lumen is minimal and
disputed (Drisaldi et al., 2003; Rane et al., 2004; Kang et al.,
2006). Even if retrotranslocation of PrP did occur, DSS-PrP ex-
pression is not an especially close mimic since this substrate
would be handled by cytosolic quality control pathways that in-
volve different machinery and are mechanistically distinct from
ER-associated degradation. Thus, while the atypical neurode-
generation caused by enforced cytosolic PrP expression is
provocative, its physiologic or pathologic relevance has been
uncertain and leaves open the issue of what pathway(s) con-
tribute to the neuronal dysfunction and phenotypes in prion
diseases.
Nonetheless, the toxicity of DSS-PrP expression in mice (Ma
et al., 2002), together with the possibility of PrPSc-mediated ER
stress (Hetz et al., 2003; Hetz and Soto, 2006) and stress-
induced translocational attenuation of PrPC (Kang et al., 2006;
Orsi et al., 2006), raised a testable hypothesis for a neurotoxic
mechanism during prion disease pathogenesis: persistent ele-
vated routing of PrP through the pQC pathway during chronic
ER stress induced by PrPSc accumulation leads to damage of se-
lected subsets of neurons and corresponding clinical symptoms.
Such a model makes two key predictions. First, PrPSc accumu-
lation should lead to ER stress and reduced translocation of
newly synthesized PrP into the ER lumen. Second, at least a sub-
set of the neurodegenerative sequelae of prion infection should
be directly inducible, even in the absence of PrPSc or misfolded
PrP aggregates, solely by changing the metabolism of PrPC to
that occurring during chronic ER stress. In this study, we have
performed experiments to test these predictions. Our results
provide a means to link PrPSc-mediated ER stress to a specific
change in PrPmetabolism that contributes to neurodegenerative
disease.
RESULTS
PrPSc Induces ER Stress and Influences PrP
Translocation
Brain tissue from scrapie-inoculated hamsters (Sc-Ha) at the end
stages of disease were compared to normal hamsters (Ha) for
expression of various proteins, including markers of ER stress.360 Developmental Cell 15, 359–370, September 16, 2008 ª2008 ElWhen equal amounts of brain homogenate were analyzed (see
total protein stain, Figure 1A), total PrP levels were increased
in the scrapie-infected tissue. The increased PrP was due to
the accumulation of PrPSc, as confirmed by its proteinase K
(PK) resistance (Figure 1B). Elevated glial fibrillary acidic protein
(GFAP) levels, corresponding to the increased astrogliosis seen
in hamster prion disease, further verified that the Sc-Ha samples
represented late stages of disease. When analyzed for various
ER markers, the Sc-Ha sample contained elevated levels (by
2- to 3-fold) of BiP, a major lumenal chaperone whose
Figure 1. PrPSc Accumulation Induces ER Stress and Reduces PrP
Translocation into the ER
(A) Total brain homogenate from normal and PrPSc-infected hamsters (‘‘nor-
mal’’ and ‘‘scrapie’’) were analyzed by staining for total proteins or immuno-
blotted for the indicated antigens. Asterisk indicates trace IgG heavy chain
that occasionally contaminates tissue homogenates from residual blood.
(B) Analysis of PrP from the samples in (A) for resistance to digestion by pro-
teinase K (PK). No protease-resistant PrP was detected in normal tissue
even upon gross overexposure of the blot (data not shown).
(C) ER microsomes from normal and PrPSc-infected hamsters were used for
in vitro translocation assays for PrP. After synthesis with 35S-Methionine, the
samples were treated with PK to digest nontranslocated products, and the
protease-protected PrP (indicative of its successful translocation into the ER
microsomes) was recovered by immunoprecipitation. Shown are autoradio-
graphs of the translocated PrP. Note that in the absence of membranes (-),
full-length PrP is not protected. In samples from animals 1 and 4 weeks post-
inoculation (before PrPSc accumulation), no difference is observed in normal
and scrapie microsomes. By contrast, at a time when PrPSc accumulation is
high (7 and 10 weeks; see Figure S1), translocation is significantly lower in in-
fectedmicrosomes relative to the uninfected control. Note that each pair of mi-
crosomes at every time point was isolated and analyzed in parallel; however,
comparisons may not be valid between time points, so the apparent increase
in translocation in normal microsomes over time may not be meaningful.sevier Inc.
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2007). In addition, another ER chaperone, the oxidoreductase
GRP58/ERp57, was also elevated. By contrast, other ER pro-
teins, such as Calnexin (a transmembrane chaperone) and
TRAPa (a component of the protein translocon), were not detect-
ably affected. These proteins serve as internal controls for non-
specific ER expansion. Thus, late stages of hamster scrapie
containing high levels of PrPSc display markers of ER stress.
To determine whether this ER stress seen in scrapie-infected
hamsters impacts the translocation of newly synthesized PrP
into the ER, we isolated microsomes from normal and infected
brain tissue and tested their functional activity for PrP import.
In this experiment, hamsters were inoculated with either saline
or PrPSc. At weekly intervals following the inoculations, one
each of the control and PrPSc-inoculated animals was sacrificed
and brain tissue used for rough microsome (RM) isolation. At the
end of ten weeks (the approximate incubation time to death), all
of the RMs were analyzed in parallel. Note that each pair of con-
trol versus infected RM at every time point represents matched
and directly comparable samples. Furthermore, since the first
four pairs of microsomes are from animals before any phenotype
is observed and before any PrPSc is detectable biochemically
(see Figure S1A available online), they represent four indepen-
dent comparisons comprising a ‘‘predisease’’ set. By contrast,
the last four pairs of microsomes have readily detectable
PrPSc accumulation in samples from the inoculated animals
(Figure S1A) and constitute a ‘‘disease’’ set.
Each of the RM samples was incubated with an in vitro trans-
lation extract supplemented with PrP transcript and 35S-Methio-
nine to allow both endogenous mRNAs and exogenously added
PrP transcript to be translated into radiolabeled proteins. Analy-
sis of the total products by autoradiography showed very similar
profiles and amounts of each band (Figure S1B). This confirmed
the uniformity of RM recovery, RNA integrity, and translation ef-
ficiency in all of the samples. To assess PrP translocation, sam-
ples were then subjected to a protease protection assay in which
only the translocated products are protected from digestion. The
protease-protected PrP that had been translocated into the RMs
was then recovered by immunoprecipitation and visualized by
autoradiography. As seen in Figure 1C, the amount of newly syn-
thesized (i.e., radiolabeled) and translocated PrP was the same
in RMs from control and PrPSc-inoculated brains at the 1 and 4
week predisease time points. By contrast, the amount of PrP
translocated into RMs from PrPSc-inoculated brains at the 7
and 10 week disease time points was noticeably less (roughly
half) than that seen in the matched control-inoculated RMs.
Averaging the four comparisons in the predisease set showed
no difference in PrP translocation into PrPSc-inoculated RMs
(103% of control; p = 0.9). By contrast, the disease set showed
a statistically lower level of translocation capacity into PrPSc-
inoculated RMs (72% of control; p < 0.05).
These results indicate that at a gross level (in which the entire
brain is averaged and treated as a single entity), PrPSc accumu-
lation induces at least some limbs of the ER stress response (as
judged by BiP and GRP58 upregulation), consistent with recent
observations in both mice and cultured cells (Hetz et al., 2005;
Hetz and Soto, 2006). More importantly, the stressed ER isolated
from these diseased brains were reduced slightly (to 70% of
control) in their translocation capacity relative to ER from nondi-Developmeseased brain. This is consistent with experiments in cultured
cells showing that several types of ER stressors all lead to de-
creased translocation of PrP (Kang et al., 2006; Orsi et al.,
2006), a phenomenon that also can be recapitulated in vitro
upon perturbation of ER lumenal proteins (Kang et al., 2006).
Clearly, new in situ methodologies for measuring translocation
will be needed to assess this effect of PrPSc on a finer scale
in vivo. That notwithstanding, the above data support the hy-
pothesis that one effect of PrPSc is to cause reduced transloca-
tion of newly synthesized PrP into the ER. This effect may be
a secondary consequence of ER stress, during which PrP is
routed at least partially into the pQC pathway to generate (at
least transiently) cytosolic PrP.
Design of a PrP Variant Constitutively Degraded
Selectively by pQC
To investigate whether increased routing of PrP into the pQC
pathway might be a contributing factor in neurodegeneration,
we needed ameans to cause this rerouting for PrP without PrPSc
accumulation or ER stress (which presumably has many other
pleiotropic effects). The molecular steps comprising pQC in-
clude SRP-dependent targeting of the nascent polypeptide to
the ER membrane, transfer to the translocon, rejection from
translocation, and release into the cytosol for proteasomal deg-
radation (Figure 2A). This series of events is spatially and mech-
anistically distinct from other pathways of proteasomal degrada-
tion (Meusser et al., 2005; Bukau et al., 2006) including failed
targeting (in which nascent PrP would interact with chaperones
in the cytosol rather than SRP) or retrotranslocation (in which
processed PrP would be extracted from the ER lumen by the cy-
tosolic VCP/p97 complex for degradation). Importantly, among
these three potential routes for cytosolic PrP degradation, only
the pQC pathway is clearly and unambiguously utilized upon
ER stress (Kang et al., 2006; Orsi et al., 2006). No evidence exists
for PrP ever being directly synthesized in the cytosol (except
upon artificial deletion of its signal sequence), and pulse-chase
studies of PrP during both normal and stressed conditions failed
to detect its retrotranslocation from the ER lumen to cytosol
(Drisaldi et al., 2003; Rane et al., 2004; Kang et al., 2006).
Thus, pQC appears to be the principal regulatory point of early
PrP biosynthesis during ER stress. Hence, to mimic the conse-
quences of ER stress on PrP metabolism, it was important that
PrP be routed selectively into the pQC pathway and not other
routes of proteasomal degradation.
To accomplish this, we replaced the PrP signal sequence with
the signal sequence from Interferon-g (Ifn; see Figure 2B) shown
previously to be competent for ER targeting, but inefficient in
translocon gating (Kim et al., 2002). As a matched control, we
also used another signal sequence (from Osteopontin [Opn])
that is comparable in length but whose targeting and gating effi-
ciency are much higher (Kim et al., 2002). Analysis of 150-mer
nascent PrP chains in vitro by crosslinking revealed that PrP,
Ifn-PrP, and Opn-PrP, but not DSS-PrP, all interact with SRP in
the cytosol (Figure 2C). Upon targeting to ER-derived micro-
somes (which did not occur for DSS-PrP; data not shown),
PrP, Ifn-PrP, and Opn-PrP each released from SRP and was
transferred to the Sec61 translocon as judged by crosslinking
(Figure 2D). However, Ifn-PrP did not make contacts with
lumenal chaperones (such as protein disulfide isomerase) asntal Cell 15, 359–370, September 16, 2008 ª2008 Elsevier Inc. 361
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(A) Schematic diagram of cytosolic quality control (cQC), pre-emptive quality control (pQC), and ER-associated degradation (ERAD). Of these, only the pQCpath-
way has been demonstrated to be utilized by PrP during ER stress (Kang et al., 2006; Orsi et al., 2006).
(B) The signal sequences and cleavage site (arrowhead) for constructs used in this study. Lysine residues used for crosslinking analyses are in bold.
(C) Crosslinking to cytosolic proteins of ribosome-associated nascent chains (RNCs) synthesized up to PrP residue 150. PrP (P), Ifn-PrP (I), Opn-PrP (O), and
DSS-PrP (D) are analyzed. The arrowhead indicates crosslinks to SRP54, confirmed by immunoprecipitation (right panel). Asterisk indicates the position of
uncrosslinked nascent chains.
(D) Crosslinking to ER proteins of RNCs synthesized to PrP residue 150. After crosslinking, the products were fractionated into membrane-associated and
lumenal proteins, shown in the left and middle panels, respectively. Open arrow indicates crosslinks to the translocon component Sec61a (verified by immuno-
precipitation; data not shown), and closed arrow indicates crosslinks to the lumenal chaperone PDI, identified by immunoprecipitation in the right panel.
(E) PrP was synthesized in the absence or presence of ER-derived RMs in a lysate supplemented with His-tagged ubiquitin. Ubiquitin-conjugated products were
captured on immoblized Co2+. The positions of PrP species representing precursor (pre), signal-cleaved (s.c.), glycosylated (glyc), and ubiquitinated (Ub)
products are indicated. Also shown are the Ubiquitin-conjugated products for DSS-PrP, illustrating its relatively poor ubiquitination.
(F) Ubiquitination analysis (as in [E]) of PrP, Ifn-PrP, and Opn-PrP in the absence and presence of RMs. The lower panel shows the total products and the upper
panel the Ubiquitin-conjugated species captured via the His-tagged ubiquitin.efficiently as either PrP or Opn-PrP (Figure 2D). Thus, Ifn-PrP is
targeted to the ER translocon via the SRP pathway, but is ineffi-
cient in its access to the ER lumen.
To determine whether this poor access to the ER lumen leads
to its subsequent release into the cytosol for degradation, we an-
alyzed PrP ubiquitination. When PrP is synthesized in vitro in the
absence of ER-derived RMs, PrP precursors become polyubi-
quitinated (Figure 2E). By contrast, inclusion of RMs in the trans-362 Developmental Cell 15, 359–370, September 16, 2008 ª2008 Ellation reaction results in PrP translocation (as evidenced by its
glycosylation) rather than cytosolic ubiquitination (which was re-
duced by over 80%). In contrast to either PrP or Opn-PrP, Ifn-PrP
showed a substantial amount (40%) of ubiquitinated products
even when synthesized in the presence of RMs (Figure 2F). Cu-
riously, DSS-PrP was poorly ubiquitinated in this same assay
(Figure 2E), indicating that its recognition and/or metabolism is
different than cytosolic full-length PrP (see Figures 3C and 4Csevier Inc.
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(A) Wild-type PrP, Ifn-PrP, and Ifn-PrP(A120L) were analyzed by in vitro translation and translocation assays. An inhibitor of glycosylation was included in all
reactions to simplify the banding pattern. Half of each sample was analyzed directly, while the remainder was digested with PK. The positions of full-length
(FL) PrP and the proteolytic fragments corresponding to CtmPrP and NtmPrP are indicated. Note that Ifn-PrP makes comparable amounts of CtmPrP as wild-type,
while Ifn-PrP(A120L) makes substantially more.
(B)Wild-type PrP, Ifn-PrP, PrP(A117V), and PrP(AV3) were expressed in N2a cells, andmicrosomes isolated from these cells were subjected to analysis for CtmPrP
by limited PK digestion. Shown are different relative amounts of undigested sample, as well as the products after digestion under ‘‘mild’’ and ‘‘harsh’’ conditions
(seeHegde et al., 1998). The PK-digested sampleswere deglycosylatedwith PNGase before analysis. In this assay, PK digestion undermild conditions generates
an 18 kD fragment corresponding to CtmPrP (indicated by asterisk). A smaller band corresponding to the C-terminal globular domain of PrP is indicated by the
arrowheads. Note that Ifn-PrP levels are very low due to its constitutive degradation (see Figure 4B), even though its rate of expression was verified to be
comparable to wild-type PrP by pulse-labeling experiments as in Figure 4A (data not shown). A band at 14 kD seen in the Ifn-PrP samples appears to be
a degradation intermediate that is sometimes observed.
(C) PrP and DSS-PrP were synthesized in vitro in the absence of ER membranes and analyzed by sucrose gradient sedimentation. An aliquot of the total trans-
lation products is also shown. Note that PrP is ubiquitinated significantly more efficiently than DSS-PrP, and that the two proteins have different sedimentation
profiles indicative of associations with different complexes.below). Thus, Ifn-PrP mimics the pQC pathway by displaying ef-
ficient SRP-dependent targeting to the translocon, poor access
to the ER lumen, release into the cytosol, and ubiquitination.
Relationship between pQC and Other Pathways of
Altered PrP Biosynthesis
Additional experiments illustrated that the Ifn-PrP paradigm is
distinct from other models of cytosolic (Ma et al., 2002) or cyto-
solically exposed transmembrane PrP (Hegde et al., 1998). A
transmembrane form (termed CtmPrP) is also generated at the
ER during PrP biosynthesis and its overrepresentation can lead
to neurodegeneration (Hegde et al., 1998, 1999). However, pre-
viousmechanistic analyses suggest that increased generation of
CtmPrP typically requires a mutation that raises the hydrophobic-
ity of the central hydrophobic region that serves as the trans-
membrane domain (Kim et al., 2001; Kim and Hegde, 2002;
Stewart and Harris, 2003). While decreasing the efficiency of
the signal sequence can facilitate CtmPrP generation, this alone
is not sufficient (see Figure S2). Direct analysis of PrP and Ifn-
PrP showed that both proteins generate comparable amounts
of CtmPrP (Figure 3A). However, there is less of the fully translo-
cated isoform for Ifn-PrP, indicating that a higher proportion was
cytosolic (consistent with the increased ubiquitination of Ifn-PrPDevelopmseen in Figure 2F). Only in the context of an additional mutation in
the transmembrane domain does the Ifn signal lead to increased
CtmPrP (Figure 3A; Kim et al., 2002). Similar results were obtained
in cultured cells (Figure 3B), where we observed that Ifn-PrP
does not generate increased CtmPrP (relative to wild-type PrP).
Instead, the majority of the protein is degraded in the cytosol
(see Figure 4), leading to its low steady state expression levels.
This is in contrast to previously characterized transmembrane
domain mutants (A117V and AV3; see Hegde et al., 1998), where
increased CtmPrP could be seen by the same assay.
These results illustrate two important points. First, compared
to wild-type PrP, Ifn-PrP does not generate significantly in-
creased levels of CtmPrP in vitro or in vivo; rather, a substantial
proportion of Ifn-PrP is cytosolic, where it is ubiquitinated
(Figure 2F) and degraded by a proteasome-dependent pathway
(see Figure 4B). Second, the cytosolically released population
of Ifn-PrP initially must have been at the translocon since it
has the potential to be inserted into the membrane, had the
transmembrane domain been sufficiently hydrophobic (e.g.,
Ifn-PrP[A120L] in Figure 3A). This is consistent with previous
in vitro analyses that demonstrated that Ifn-PrP targets efficiently
to the ER membrane, but does not mediate efficient transloca-
tion (Fons et al., 2003). Thus, we can conclude that Ifn-PrPental Cell 15, 359–370, September 16, 2008 ª2008 Elsevier Inc. 363
Developmental Cell
Reduced PrP Translocation Causes Neurodegenerationmimics the pQC pathway to generate cytosolically localized
PrP that, despite targeting to the ER membrane, remains
unprocessed and is not membrane inserted in the CtmPrP
configuration.
We also considered whether DSS-PrP, which results in cyto-
solically localized PrP, is comparable to or different from cyto-
solic PrP generated by the pQC pathway. We found that PrP
containing a signal sequence interacts with different proteins (in-
cluding SRP) than DSS-PrP interacts with during its synthesis on
the ribosome (as judged by crosslinking; Figure 2C). More impor-
tantly, PrP andDSS-PrPwere found to be in different-sized com-
plexes in the cytosol when analyzed by sedimentation through
sucrose density gradients (Figure 3C). In this experiment, it is
also readily apparent that cytosolic full-length PrP is ubiquiti-
nated significantly more efficiently than DSS-PrP, a conclusion
confirmed by direct ubiquitination assays (see Figure 2E). These
Figure 4. Ifn-PrP Mimics pQC In Vivo in the Absence of ER Stress
(A) ER translocation of the indicated PrP constructs in transiently transfected
HeLa cells subjected to acute ER stress (15 min) by Ca2+ depletion using
thapsigargin (Tg). Translocation was quantified using relative glycosylation
efficiency and is indicated below the respective lanes. The positions of ungly-
cosylated (CHO) and glycosylated (+CHO) species of PrP are indicated. Note
that protein synthesis is reduced in stressed cells due to PERK-mediated
phosphorylation of eIF2a.
(B) N2a cells transiently transfected with Ifn-PrP were treated with proteasome
inhibitor (10 mMMG132) for 0, 2, or 4 hr as indicated and analyzed by immuno-
blotting. Samples were separated into detergent-soluble (S) and insoluble (P)
fractions before analysis. ‘‘4+20’’ indicates samples from cells treated with in-
hibitor for 4 hr, and cultured in the absence of inhibitor for an additional 20 hr.
The last lane is a marker for mature PrP from cells expressing wild-type PrP.
(C) N2a cells transiently transfected with DSS-PrP were treated with protea-
some inhibitor (10 mM MG132) for 4 hr as indicated, and either harvested im-
mediately, or cultured for an additional 4–24 hr in the absence of inhibitor.
All samples were analyzed for DSS-PrP by immunoblotting with 3F4 antibody.
(D) N2a cells transiently transfected with Ifn-PrP or empty vector were sepa-
rated into detergent-soluble (S) and insoluble (P) fractions before analysis by
immunoblot using a PrP antibody that detects both endogenous PrP and
Ifn-PrP. Note the lack of changes to endogenous PrP in cells expressing
Ifn-PrP (most of which is found in the insoluble fraction as unglycosylated
species).364 Developmental Cell 15, 359–370, September 16, 2008 ª2008 Elresults collectively indicate that nontranslocated PrP made by
the pQC pathway (in which N- and/or C-terminal signals are un-
processed) is distinct from cytosolic PrP artificially generated by
deletion of its signal sequences. Importantly, the former species
is clearly physiologically relevant since it is generated during dif-
ferent types of ER stress (Kang et al., 2006; Orsi et al., 2006), in-
cluding potentially the stress induced by PrPSc accumulation
(Figure 1). Because Ifn-PrP faithfully mimics the pQC pathway
taken by PrP during ER stress, this construct represents a valid
model for one (of presumably many) consequences of PrPSc
accumulation.
Validation of the Ifn-PrP Model of pQC in Cultured Cells
Analysis of Ifn-PrP in pulse-labeled cultured cells confirmed that,
in vivo, its translocation into the ER lumen (as judged by its gly-
cosylation) during nonstressed conditions is comparable to the
level observed for PrP during acute stress induced by ER cal-
ciumdepletion (Figure 4A). Opn-PrP translocationwas compara-
ble to or slightly higher than PrP, and changed little during ER
stress. That nontranslocated Ifn-PrPwas indeed being degraded
in the cytosol was evidenced by accumulation of unglycosylated
precursor molecules upon proteasome inhibition and its subse-
quent degradation upon removal of the inhibitor (Figure 4B). Of
note, DSS-PrP aggregates generated during proteasome inhibi-
tion appear to be relatively refractory to degradation even when
inhibition is alleviated (Figure 4C). This is consistent with its de-
creased efficiency of recognition by the ubiquitination machinery
in vitro (Figure 3D), further confirming that the metabolism of
DSS-PrP is distinct from the pathway taken by Ifn-PrP. Impor-
tantly, the constitutive degradation of Ifn-PrP via pQC did not af-
fect the expression, metabolism, or properties of endogenous
PrP, whose levels, solubility, and glycosylation pattern remained
unaltered (Figure 4D). This further illustrates that Ifn-PrP routed
into the pQC pathway remains topologically distinct from and
does not interact either physically or functionally with PrP routed
into the secretory pathway. Thus, Ifn-PrP represents a version of
PrP whose biosynthesis, trafficking, and metabolism under nor-
mal conditions closely mimics that seen for PrP during ER stress.
We could therefore now ask whether elevated and chronic deg-
radation of PrP via the pQC pathway, an event that occurs during
ER stress such as that induced by PrPSc accumulation (Figure 1),
could be a contributing factor in neurodegeneration.
The Consequences of Constitutive pQC of PrP
in Transgenic Mice
The Opn-PrP and Ifn-PrP coding regions in a well-characterized
cosmid containing 35 kB of the PrP promoter (Scott et al.,
1992) were used to generate transgenic mice. In contrast to
Opn-PrP, the Ifn-PrP transgene apparently had adverse conse-
quences during early development and produced fewer rela-
tively small founder animals, several of which died within two
months after birth (see the Supplemental Data). These observa-
tions suggest that generation of cytosolic PrP during develop-
ment via the pQC pathway might be detrimental for reasons
that remain to be studied. This effect precluded the generation
of transgenic mice expressing Ifn-PrP at high or even wild-type
levels (see Figure S3). Nonetheless, we obtained several trans-
genic founders, one of which allowed the generation of a stablesevier Inc.
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neurologic phenotypes.
While transgenic Ifn-PrP mice were noticeably smaller than
either nontransgenic littermates or Opn-PrP transgenics, they
had a comparable lifespan (over 700 days) and did not show
any increased rate of early death relative to Opn-PrP controls
(Figure 5A). Note that the death of some animals (in both trans-
genic lines) by 200 days is unrelated to the PrP transgenes or
to neurodegenerative illnesses. Because the potential pheno-
types of these animals could not necessarily be predicted, we
have plotted all deaths including those resulting from animal
fighting and intercurrent illnesses, such as infections and tumors.
Consistently however, Ifn-PrP mice showed a progressive age-
dependent phenotype characterized by a rough hair coat, slight
ataxia that worsened over time, hunched posture (kyphosis), and
occasional movement disorder and seizure (Figures 5B and 5C,
and Movies S1–S6). Young mice (2–3 months old) showed only
subtle defects in coordination and hind limb strength. More ob-
vious impairments including relative unresponsiveness to exter-
nal stimuli and altered gait were only apparent after 18–24
months. Comparable results were obtained with an independent
founder animal carrying the Ifn-PrP transgene, arguing for the
specificity of the phenotype to the transgene rather than an un-
related effect. However, other stable breeding lines were not ob-
tained despite repeated attempts at breeding encompassing
over 15 litters (see the Supplemental Data).
At the level of gross pathology, the brains of Ifn-PrP mice were
notably smaller than Opn-PrP mice, consistent with their overall
Figure 5. Phenotype of Ifn-PrP Transgenic Mice with Constitutive
pQC of PrP
(A) Lifespans of Ifn-PrP and Opn-PrP mice. All causes of death are included in
the analysis except those mice that were sacrificed prematurely for analysis.
(B) Representative Opn-PrP and Ifn-PrP mice at 2 months. Note rough hair
coat and smaller size of Ifn-PrP mouse.
(C) Representative Ifn-PrP mouse at 2 yr. Note kyphosis (arrow), rough hair
coat, and abnormal gait (Movies S2, S3, and S6).Developmesmaller size (Figure 6A). Surprisingly however, little or no patho-
logic changes were observed in adolescent or young adult mice
(Figures 6B–6H). Only after 18 months were very modest age-
dependent spongiform changes observed in the cerebellum,
hippocampus, and midbrain (Figures 6B–6D). These neuropath-
ologic effects were only marginally greater than that seen simply
as a consequence of old age, despite the readily apparent clini-
cal phenotype. Notably, no gross degeneration of any of the cer-
ebellar layers was observed at any age, and the number and
morphology of Purkinje cells remained normal throughout life
(Figure 6E). Analysis for reactive astrocytosis by GFAP staining
showed very modest, age-dependent increases in the number
and size of astrocytes in the hippocampal region of Ifn-PrP
mice relative to Opn-PrP transgenic mice (Figure 6F). Staining
of 2 year old mice with Fluoro-Jade C, a commonly used marker
for degenerating neurons, showed increased signal for Ifn-PrP
relative to Opn-PrP in both the hippocampus and in parts of
the cerebral cortex (Figure 6G). No Fluoro-Jade C staining in
any brain regions was observed in younger Ifn-PrP mice (less
than 1 year old; data not shown). Thus, the phenotype of Ifn-
PrPmice is distinct from the highly atypical early onset cerebellar
degeneration inDSS-PrP-expressingmice (Ma et al., 2002), sug-
gesting that the different pathways of trafficking and degradation
of these two PrP variants (Figure 2A) have different functional
consequences. More importantly, the progressive age-depen-
dent clinical phenotype of Ifn-PrP is more akin to the clinical
picture of both genetic and transmissible prion diseases.
Quantitation of pQC in Ifn-PrP Transgenic Mice
Biochemical analyses on brain tissue and cells from transgenic
Ifn-PrP mice showed that Ifn-PrP expression had no effect on
the levels or modification of endogenous PrP (data not shown;
see also Figure 7B), consistent with the results from cell culture
(Figure 4D). Furthermore, steady-state Ifn-PrP expression levels
in whole brain, and even neurons cultured from transgenic new-
borns, was extremely low (Figure S4 and Figure 7A). In addition,
focal accumulations were not detected by PrP immunohisto-
chemistry of either cultured neurons or brain sections (data not
shown). This is consistent with the expectation from in vitro stud-
ies that a substantial fraction of Ifn-PrP should be constitutively
degraded by the very rapid and efficient pQC pathway. Indeed,
proteasome inhibition of neuronal cultures caused a progressive
accumulation of nonglycosylated Ifn-PrP, but no change in the
mature cell surface population (Figure 7A).
To quantify the rate of pQC-mediated degradation in Ifn-PrP
mice, we analyzed primary neurons cultured from transgenic
newborns. Pulse-labeling and immunoprecipitation revealed
Ifn-PrP expression predominantly in a nonglycosylated form
that was stabilized by proteasome inhibition (Figure 7B). Using
an antibody that recognizes both the transgene-expressed
Ifn-PrP and endogenous mouse PrP, we could deduce that
5%–10% of total PrP was represented by Ifn-PrP. This is
almost certainly an underestimate because not only is Ifn-PrP
rapidly degraded, but even in the presence of proteasome in-
hibitors, Ifn-PrP would migrate heterogeneously due to its
polyubiquitination.
As a second approach to quantify the level of Ifn-PrP expres-
sion and provide an upper limit for the extent of pQC, we deter-
mined the relative abundances of Ifn-PrP, Opn-PrP, andntal Cell 15, 359–370, September 16, 2008 ª2008 Elsevier Inc. 365
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Reduced PrP Translocation Causes NeurodegenerationFigure 6. Histologic Analysis of Ifn-PrP Mice Reveals Mild Neurodegeneration
(A–D) H&E stained sagittal brain sections show no alterations to gross brain morphology or development in Ifn-PrP or Opn-PrP mice at either2 months or2 yr
of age. Green boxes indicate regions shown in greater detail in (B–D).
(E) Immunostaining for calbindin to visualize Purkinje cells (brown). Note that neither the Purkinje cells’ granular layer (left) or molecular layer (right) are affected
grossly in Ifn-PrP mice.
(F) GFAP staining of Ifn-PrP or Opn-PrP mice at either 2 months or 2 yr of age. Shown is a region of hippocampus where age-dependent increase in reactive
astrocytes is observed in Ifn-PrP mice beyond that seen in old Opn-PrP mice.
(G) Fluoro-Jade C staining of Ifn-PrP or Opn-PrP mice at 2 yr of age. Shown are regions where increased staining is observed in Ifn-PrP mice. Note that no
staining was observed in young mice of either genotype (data not shown).366 Developmental Cell 15, 359–370, September 16, 2008 ª2008 Elsevier Inc.
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was isolated from whole brain tissue, quantified, and used in
RT-PCR reactions containing serial dilutions of template. Syn-
thetic mRNAs generated by in vitro transcription served as
standards to determine absolute mRNA abundances. From
these analyses, we determined that Opn-PrP and Ifn-PrP
mRNAs are expressed at 4 3 107 and 3.3 3 106 copies per
mg total brain tissue, respectively. Based on semiquantitative
immunoblotting (Figure S4), we know that Opn-PrP protein levels
are 2-fold higher than endogenous PrP. Given that their 50 and
30UTRs are comparable and they are expressed in the same sets
of cells by the transgenic promoter used in our study, we can rea-
sonably infer that the rates of synthesis of the respective proteins
mirror the mRNA levels. We therefore estimate endogenous PrP
mRNA levels to be 23 107 copies per mg brain tissue (roughly
6-fold higher than Ifn-PrP mRNA levels). These values place an
upper limit on the absolute amount of PrP routed into pQC in
the Ifn-PrPmice at15%–20% (if all of the Ifn-PrP was being de-
graded by this pathway). Analysis of an independent Ifn-PrP
founder animal that developed a very similar phenotype showed
Figure 7. Quantitation of pQC in Ifn-PrP Transgenic Mice
(A) Expression of Ifn-PrP in mixed cortical cell cultures prepared from newborn
transgenic and nontransgenic mice after treatment with proteasome inhibitor
(10 mMMG132) for the indicated times. For comparison, PrP expression in nor-
mal hamster brain is shown. Detection was with the 3F4 monoclonal antibody
selective to hamster (and notmouse) PrP. Two exposures of the blot are shown
to illustrate the very low level steady-state expression of Ifn-PrP, and the selec-
tive increase in the unglycosylated cytosolic form of PrP upon proteasome
inhibition.
(B) Cortical cultures as in (A) were pretreated with MG132 as indicated, pulse-
labeled for 1 hr with 35S-Methionine in the absence or presence of MG132, and
immunoprecipitated with either 3F4 (to selectively recover the transgenically
expressed Ifn-PrP) or a pan-PrP antibody to recover both endogenous and
transgenic PrPs. The white arrow indicates the position of unglycosylated
(and nontranslocated) Ifn-PrP, seen selectively when the proteasome is in-
hibited. This is also seen in the total PrP immunoprecipitates, where it repre-
sents 10% of total PrP synthesized.Developmecomparable (within 2-fold) mRNA levels by this same analysis.
Thus, in both cases, Ifn-PrP is not being overexpressed relative
to endogenous PrP. Using the above biochemically determined
value of 10% as a minimum (Figure 7B), we can estimate that
the overall level of pQC in our Ifn-PrP mouse line must be in
the range of 10%–20% of endogenous PrP levels.
These results indicate that Ifn-PrPmicemimic the situation ex-
pected under relatively mild to moderate ER stress conditions:
the majority of synthesized PrP continues to be translocated
into the ER, while a small proportion is degraded via pQC in
the cytosol. This routing of PrP through the pQC degradation
pathway at a modest rate for prolonged times in cells that nor-
mally express PrP causes phenotypic and histologic changes
that partially overlap with the wide spectrum of neuropathologic
sequelae in prion diseases. This is consistent with our analysis
of scrapie-infected hamsters where ER stress was evident
(Figure 1A) and corresponds to a small but significant decrease
in PrP translocation capacity (Figure 1C). Interestingly, the phe-
notype of Ifn-PrP mice despite the absence of PrP accumulation
illustrates that PrP-mediated neuronal dysfunction can be
uncoupled from either PrPSc or aggregate deposition.
DISCUSSION
The most important implication of this study is a potential means
to link PrPSc, via ER stress and pQC, to a PrP-dependent path-
way of neurotoxicity. What has been vexing thus far is how rather
generic consequences of PrPSc accumulation, such as reduced
proteasome activity (Kristiansen et al., 2007) or ER stress (Hetz
et al., 2003), could cause selective pathology that is dependent
on active PrP expression. Our results provide one answer to
this problem by demonstrating that the consequence of ER
stress for nascent PrP, increased routing through pQC, is in itself
sufficient to cause cell-type-selective neuronal damage. How-
ever, it should be emphasized that an effect of PrPSc on nascent
PrP translocation is not likely to be the only pathway that contrib-
utes to neurodegeneration. Indeed, Ifn-PrP mice show a rela-
tively mild neurodegenerative phenotype that recapitulates
only a subset of pathology seen with a bona fide prion disease.
One can therefore conclude that an effect on PrP translocation
is only one of several consequences of prion infection and PrPSc
accumulation. Importantly however, other putative mechanisms
of neurotoxicity must necessarily be dependent on active
synthesis of new PrP (Brandner et al., 1996; Mallucci et al.,
2003, 2007). Such contributing factors could include a hypothet-
ical neurotoxic intermediate generated by the PrPC to PrPSc
conversion process (Collinge and Clarke, 2007), increased
CtmPrP (Hegde et al., 1999), or decreased proteasome activity
(Kristiansen et al., 2007). The latter might further exacerbate
the consequences of pQC by reducing degradation of nontrans-
located PrP, leading to its increased accumulation and toxicity.
Each of these and other contributing factors is likely to affect dif-
ferent subsets of cell types to differing extents. This could ex-
plain why the phenotypes of prion diseases are not only diverse
and complex, but alsomore severe thanmodels that recapitulate
only one downstream consequence like reduced PrP transloca-
tion (this study) or increased CtmPrP production (Hegde et al.,
1998). Thus, the pleiotropic cell biological consequences
of PrPSc accumulation are likely to influence nascent PrPntal Cell 15, 359–370, September 16, 2008 ª2008 Elsevier Inc. 367
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of which could contribute to the overall phenotype.
Our results underscore that even amodest deviation from nor-
mal PrP biosynthesis at the ER can have tangible neurologic con-
sequences in certain cell types over the life of an organism. This
is analogous to the finding that a very slight increase in the pro-
duction of CtmPrP at the ER can cause region-selective neurode-
generation in both mouse models and inherited human disease
(Hegde et al., 1998, 1999). In the Ifn-PrP model, elevated CtmPrP
could not be detected in either cell culture (Figure 3A) or brain
tissue (Figure S4C), indicating that the primary cause of the phe-
notype in these mice is nontranslocated PrP. In both cases, neu-
rodegeneration is not simply a consequence of aggregation or
PrP accumulation, but instead seems highly selective to minor
and/or transiently generated forms of PrP that would easily elude
detection. Hence, our results are not inconsistent with previous
difficulty in detecting cytosolic PrP in prion infected tissue using
an anti-signal sequence antibody (Stewart and Harris, 2003). Be-
cause nontranslocated PrP does not accumulate due to its rapid
ubiquitination and degradation (Kang et al., 2006), it is not
surprising that its presence was not detected by an antibody of
limited sensitivity. Nonetheless, cytosolic PrP generated via the
pQC pathway can cause neurodegeneration at levels that are
essentially undetectable at steady state.
At present it is unclear why routing of PrP through pQC leads
to the observed neurodegenerative phenotype. One intriguing
possibility is that transient exposure to the cytosol permits inap-
propriate interactions between PrP and proteins that are ordinar-
ily not accessible. Such putative interacting proteins may be
selectively expressed or functionally more critical in some cell
types than others, thereby explaining the region-specific pheno-
type. In support of such a model, it is worth noting that CtmPrP is
also partially exposed to the cytosol and causes region-selective
degeneration despite its widespread overexpression (Hegde
et al., 1998). It will therefore be interesting to determine whether
the N terminus of PrP, which is exposed to the cytosol in both
CtmPrP and cytosolic PrP, makes inappropriate interactions
that lead to cellular dysfunction.
It is noteworthy that a slight inefficiency in the signal sequence
of PrP underlies both the routing of PrP through pQC during
stress (Kang et al., 2006) and generation of CtmPrP caused by
mutations in the potential transmembrane domain (Kim and
Hegde, 2002). Because the signal-translocon interaction ap-
pears to be modulatable in trans by either specific factors (Voigt
et al., 1996; Fons et al., 2003) or changes in cellular conditions
(Levine et al., 2005; Kang et al., 2006), this specific step in bio-
synthesis of PrP may be especially susceptible to perturbation.
Conversely, generation of both CtmPrP and cytosolic PrP (even
during pQC) can be bypassed by improving signal sequence ef-
ficiency (Kim and Hegde, 2002; Rane et al., 2004; Kang et al.,
2006). It may therefore be possible to alleviate at least some of
the neurotoxic consequences of PrPSc or certain mutations by
enforced translocation into the ER to avoid cytosolic exposure.
While this may be beneficial under some circumstances, consti-
tutive translocation is clearly detrimental under conditions of ER
stress when the maturation capacity of the ER lumen is compro-
mised (Kang et al., 2006). The ability of PrP to be routed into the
pQCpathway appears to have evolved for avoiding itsmisfolding
in the ER during stress. Thus, at least some features of the path-368 Developmental Cell 15, 359–370, September 16, 2008 ª2008 Elogenesis of prion diseases may be an adverse consequence of
a normally beneficial quality-control pathway dependent on
translocational regulation.
More generally, ER stress induced by other diverse causes
could over time contribute to cellular dysfunction in part by its
effect on protein translocation into the ER. Intriguingly, woozy
mutant mice that are deficient in the BiP cochaperone Sil1 also
result in neurodegeneration, albeit with different features than
the Ifn-PrP mice (Zhao et al., 2005). This mutation seems both
to cause ER stress, and in a yeast model system, reduced pro-
tein translocation efficiency (Tyson and Stirling, 2000). It is
attractive to speculate that a subtle deficiency in ER function
by any of several mechanisms may lead to a modest increase
in pQC, reduced translocation of PrP (and other proteins whose
cytosolic localization could be detrimental), and regional neuro-
degeneration over time. Consistent with such amodel, ER stress
is a commonly observed feature of various neurodegenerative
diseases (Lindholm et al., 2006; Hetz and Soto, 2006). Thus, mis-
localization of proteins at very low levels for extended time pe-
riods might be amore general mechanism of cellular dysfunction
in slowly progressing neurodegenerative diseases.
EXPERIMENTAL PROCEDURES
Constructs and Antibodies
PrP, Ifn-PrP, Opn-PrP, and DSS-PrP constructs all contained the mature do-
main of hamster PrP. The Ifn and Opn signal sequences were of porcine and
rat origin and have been characterized previously (Kim et al., 2002). DSS-PrP
encodes an initiating methionine and residues 23–230 of hamster PrP (Ma
et al., 2002). Ifn-PrP(A120L) is identical to Ifn-PrP except a Leu for Ala change
at residue 120 (Kim et al., 2002). PrP(A117V) and PrP(AV3) have been charac-
terized previously (Hegde et al., 1998). Antibodieswere from the following sour-
ces: 3F4 mouse monoclonal against hamster PrP (Covance, Princeton, NJ);
GFAP (Novus, Littleton, CO); BiP, GRP58/ERP57, Calnexin, and PDI (Assay
Designs, Ann Arbor, MI); Calbindin (Sigma, St. Louis, MO); TRAPa (Fons
et al., 2003); PrP-A (raised by us against a synthetic peptide encoding
KKRPKPGGWNTGGSRYC conjugated to Keyhole limpet hemocyanin [KLH]).
In Vitro and Cell Culture Analysis
Translation of PrP (and related constructs) in a cell-free system derived from
reticulocyte lysate, translocation into canine pancreatic RMs, analysis of na-
scent chain interactions with crosslinking, and analysis of topology were per-
formed using previously published methods (Kim et al., 2002; Kim and Hegde,
2002; see the Supplemental Experimental Procedures for more details). Anal-
ysis of ubiquitination was aided by inclusion in the translation system of excess
His-Ubiquitin (5 mM, from Boston Biomed, Cambridge, MA). Deubiquitination
enzymes were inhibited with Ubiquitin-aldehyde (0.5 mM) and proteasome ac-
tivity inhibited by the Hemin present in the translation extract. After the trans-
lation reaction, samples were denatured in 1% SDS, and the ubiquitinated
products captured using Talon resin (Invitrogen, Carlsbad, CA). Sucrose gra-
dient analysis of in vitro translation products was through 10%–50% (w/v) gra-
dients (55,000 rpm, 1 hr, 4C, in Beckman TLS-55 rotor) containing 100 mM
KAc, 2 mM MgAc2, 50 mM HEPES. Cell culture, transfections, induction of
ER stress with thapsigargin, and analysis of PrP translocation under non-
stressed and stressed conditions were as described (Kang et al., 2006). Anal-
ysis of PrP products for accumulation upon proteasome inhibition and frac-
tionation by their solubility in nondenaturing detergents was as before (Rane
et al., 2004). Microsomes were isolated from cultured cells or brain tissue by
standard subcellular fractionation (Hegde et al., 1998). Analysis for CtmPrP
by limited protease digestion was as before (Hegde et al., 1998).
Transgenic Mice
The Ifn-PrP and Opn-PrP constructs were subcloned into a well-characterized
cosmid in which 35 kb of the PrP promoter is used to drive transgenesevier Inc.
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Reduced PrP Translocation Causes Neurodegenerationexpression in physiologically relevant tissues and cells (Scott et al., 1992).
Transgenic mice were made in the FVB background by standard methods,
founders identified by Southern blotting (using the transgene as a probe),
and positive progeny in subsequent breedings identified by PCR genotyping
using transgene-specific primers. Histologic analysis was as described
(Hegde et al., 1998). Fluoro-Jade C was obtained from Chemicon International
(Billerica, MA) and staining was as recommended by the manufacturer. Pur-
kinje cells were detected in formalin-fixed sections using anti-Calbindin
D28k (Sigma) and HRP-conjugated secondary antibodies. Mixed population
neuronal cultures for analysis of expression were prepared using minor mod-
ifications of standard methods (Lu et al., 1998), and analyzed after 7–10 d.
Labeling was with 0.1 mCi per ml of 35S-Methionine for 1 hr in Methionine-
free media on cells pretreated with 10 uM MG132 as indicated in the figure
legends. Harvesting of cells and analysis by immunoprecipitation and immu-
noblots was as before (Rane et al., 2004).
Miscellaneous
Inoculation of hamsters with Sc237 prions and analysis for PrPSc by PK diges-
tion was as before (Hegde et al., 1998, 1999). PrPSc digestions were for 1 hr at
37C with 0.1 mg/ml PK. Isolation of microsomes from freshly harvested brain
tissue was as before (Hegde et al., 1998). The final microsome pellet from one
half of the hamster brain was resuspended in 50 ml of physiologic salt buffer
(PSB: 100 mM KAc, 2 mM MgAc2, 50 mM HEPES [pH 7.4], 1 mM DTT,
250 mM sucrose), frozen in liquid N2, and stored at 80C. Translocation
assays used 1 ml brain microsomes and 9 ml of a standard translation mix
(Fons et al., 2003) containing 35S-Methionine, reticulocyte lysate, an acceptor
peptide to inhibit glycosylation, and in vitro synthesized PrP transcript. Reac-
tions were allowed to proceed for 40 min at 26C before placing on ice. An
aliquot (1 ml) was removed and analyzed directly to assess endogenous
mRNA translation products (see Figure S1B). The remainder was digested
with 0.5 mg/ml PK on ice for 1 hr to remove any nontranslocated products.
The samples were then inactivated with PMSF, boiled in 10 volumes of 1%
SDS, and the translocated PrP products were recovered by immunoprecipita-
tion with 3F4 antibody.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, four
figures, and six movies and can be found with this article online at http://
www.developmentalcell.com/cgi/content/full/15/3/359/DC1/.
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